Company Overview
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.
Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.